On March 1, 2023 RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, reported that Shaun Bagai, Chief Executive Officer, will be presenting at the 35th Annual Roth Conference, to be held March 12-14, 2023, in Dana Point, California (Press release, Renovorx, MAR 1, 2023, View Source [SID1234628021]). To register for the event, visit the conference website.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the presentation, Mr. Bagai will discuss the company’s mission to become a leading provider in oncology therapy by disrupting the standard of care (intravenous systemic chemotherapy) treatment of difficult-to-treat cancers. Mr. Bagai will review how its lead product candidate, RenovoGem , which utilizes RenovoRx’s proprietary therapy platform, RenovoTAMP, may provide a potential targeted intra-arterial treatment option to solid tumors. The goals of the Company’s therapy platform are to improve quality of life for patients diagnosed with cancer by reducing the debilitating side effects typical of the standard of care treatment and to extend patient survival. Additionally, Mr. Bagai will give an update on the Company’s pivotal Phase III TIGeR-PaC clinical trial which has its first interim analysis targeted for reporting early this year.
Conference Details
Event Name: 35th Annual Roth Conference
Date: March 13, 2023
Presentation: 2:00 PM Pacific Time (11:00 AM Eastern Time)
Location: Dana Point, CA
RenovoRx leadership will be available during the conference for one-on-one meetings with the investment community. To schedule a meeting please reach out to your Roth representative or by emailing KCSA Strategic Communications: [email protected].
The live audio webcast and replay will be available in the investor relations section of the Company’s website.